Drug Profile
L 735821
Latest Information Update: 02 Aug 2006
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Class III antiarrhythmics
- Mechanism of Action Calcium channel antagonists; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 02 Aug 2006 Discontinued - Preclinical for Arrhythmias in USA (unspecified route)
- 09 Sep 1997 New profile
- 09 Sep 1997 Preclinical development for Arrhythmias in USA (Unknown route)